Raymond James on Kalaris (KLRS): 'We continue to expect Kalaris to resume dosing in 2Q26 '
Tweet Send to a Friend
Raymond James analyst Chris Raymond reiterated a Strong Buy rating and $23.00 price target on Kalaris (NASDAQ: KLRS).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
